Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$1.61 - $5.2 $154,440 - $498,815
-95,926 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$2.87 - $6.29 $38,173 - $83,663
13,301 Added 16.1%
95,926 $291,000
Q3 2021

Nov 15, 2021

BUY
$4.91 - $9.07 $139,566 - $257,814
28,425 Added 52.44%
82,625 $515,000
Q2 2021

Aug 16, 2021

BUY
$7.82 - $13.8 $142,081 - $250,732
18,169 Added 50.43%
54,200 $462,000
Q1 2021

May 17, 2021

BUY
$13.0 - $19.34 $468,403 - $696,839
36,031 New
36,031 $552,000

Others Institutions Holding BCEL

About Atreca, Inc.


  • Ticker BCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,876,000
  • Description
  • Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...
More about BCEL
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.